P
Pietro Viggiani
Publications - 16
Citations - 801
Pietro Viggiani is an academic researcher. The author has contributed to research in topics: Bedaquiline & Tuberculosis. The author has an hindex of 11, co-authored 16 publications receiving 630 citations.
Papers
More filters
Journal ArticleDOI
Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study
Sergey Borisov,Keertan Dheda,Martin Enwerem,Rodolfo Romero Leyet,Lia D'Ambrosio,Rosella Centis,Giovanni Sotgiu,Simon Tiberi,Simon Tiberi,Jan-Willem C. Alffenaar,Andrey Maryandyshev,Evgeny Belilovski,Shashank Ganatra,Alena Skrahina,Onno W. Akkerman,Alena Aleksa,Rohit Amale,Janina Artsukevich,Judith Bruchfeld,Jose A. Caminero,Isabel Carpena Martinez,Luigi Codecasa,Margareth Pretti Dalcolmo,Justin T Denholm,Paul Douglas,Raquel Duarte,Aliasgar Esmail,Mohammed Fadul,Alexey Filippov,Lina Davies Forsman,Mina Gaga,Julia Amaranta Garcia-Fuertes,José-María García-García,Gina Gualano,Jerker Jonsson,Heinke Kunst,Jillian S.Y. Lau,Barbara Lazaro Mastrapa,Jorge Lazaro Teran Troya,Selene Manga,Katerina Manika,Pablo González Montaner,Jai B Mullerpattan,Suzette Oelofse,Martina Ortelli,Domingo Palmero,Fabrizio Palmieri,Antonella Papalia,Apostolos Papavasileiou,Marie-Christine Payen,Emanuele Pontali,Carlos Robalo Cordeiro,Laura Saderi,Tsetan Dorji Sadutshang,Tatsiana Sanukevich,Varvara Solodovnikova,Antonio Spanevello,Sonam Topgyal,Federica Toscanini,Adrian R Tramontana,Zarir F Udwadia,Pietro Viggiani,Veronica White,Alimuddin Zumla,Giovanni Battista Migliori +64 more
TL;DR: Bedaquiline-containing regimens achieved high conversion and success rates under different nonexperimental conditions, and is safe and effective in treating MDR- and XDR-TB patients.
Journal ArticleDOI
Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report
Sergey Borisov,Edvardas Danila,Andrei Maryandyshev,Margareth Pretti Dalcolmo,Skaidrius Miliauskas,Liga Kuksa,Selene Manga,Alena Skrahina,Saulius Diktanas,Luigi Codecasa,Alena Aleksa,Judith Bruchfeld,Judith Bruchfeld,Antoniya Koleva,Alberto Piubello,Zarir F Udwadia,Onno W. Akkerman,Evgeny Belilovski,Enrique Bernal,Martin J. Boeree,Julen Cadiñanos Loidi,Qingshan Cai,Jose Joaquin Cebrian Gallardo,Masoud Dara,Edita Davidavičienė,Lina Davies Forsman,Lina Davies Forsman,Jorge De Los Rios,Justin T Denholm,Jacinta Drakšienė,Raquel Duarte,Seifeldin Eltaeb Elamin,Nadia Escobar Salinas,Maurizio Ferrarese,Alexey Filippov,Ana Garcia,José-María García-García,Ieva Gaudiesiute,Blagovesta Gavazova,Regina Gayoso,R. Rosso,Vygantas Gruslys,Gina Gualano,Wouter Hoefsloot,Jerker Jonsson,Elena Khimova,Heinke Kunst,Rafael Laniado-Laborín,Yang Li,Cecile Magis-Escurra,Vinicio Manfrin,Valentina Marchese,Elena Martínez Robles,Alberto Matteelli,Jesica Mazza-Stalder,Charalampos Moschos,Marcela Muñoz-Torrico,Hamdan Mustafa Hamdan,Birutė Nakčerienė,Laurent P. Nicod,Magnolia Nieto Marcos,Domingo Palmero,Fabrizio Palmieri,Apostolos Papavasileiou,Marie-Christine Payen,Agostina Pontarelli,Sarai Quirós,Adrian Rendon,Laura Saderi,Agnese Šmite,Ivan Solovic,Mahamadou Bassirou Souleymane,Marina Tadolini,Martin van den Boom,Marisa Vescovo,Pietro Viggiani,Askar Yedilbayev,Rolandas Zablockis,Dmitry Zhurkin,Matteo Zignol,Dina Visca,Antonio Spanevello,Jose A. Caminero,Jan-Willem C. Alffenaar,Simon Tiberi,Simon Tiberi,Rosella Centis,Lia D'Ambrosio,Emanuele Pontali,Giovanni Sotgiu,Giovanni Battista Migliori +90 more
TL;DR: This global project (658 patients from 26 countries) demonstrates aDSM is feasible and serious adverse events of recommended drugs are reasonably low (overall 57 out of 504, 11.3%), but implementation needs scaling up to support patient-centred care.
Journal ArticleDOI
Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB.
Simon Tiberi,Marie-Christine Payen,Giovanni Sotgiu,Lia D'Ambrosio,Valentina Alarcon Guizado,Jan-Willem C. Alffenaar,Marcos Abdo Arbex,Jose A. Caminero,Rosella Centis,Saverio De Lorenzo,Mina Gaga,Gina Gualano,Aurora Jazmín Roby Arias,Anna Scardigli,Alena Skrahina,Ivan Solovic,Giorgia Sulis,Marina Tadolini,Onno W. Akkerman,Edith Alarcon Arrascue,Alena Aleska,Vera Avchinko,Eduardo Henrique Bonini,Felix Antonio Chong Marin,Lorena Collahuazo López,Gerard de Vries,Simone Dore,Heinke Kunst,Alberto Matteelli,Charalampos Moschos,Fabrizio Palmieri,Apostolos Papavasileiou,Antonio Spanevello,Dante Vargas Vasquez,Pietro Viggiani,Veronica White,Alimuddin Zumla,Giovanni Battista Migliori +37 more
TL;DR: The nondifferent outcomes and bacteriological conversion rate observed in cases who were more severe than controls might imply that meropenem/clavulanate could be active in treating MDR- and XDR-TB cases.
Journal ArticleDOI
Comparison of effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB
Simon Tiberi,Giovanni Sotgiu,Lia D'Ambrosio,Rosella Centis,Marcos Abdo Arbex,Edith Alarcon Arrascue,Jan-Willem C. Alffenaar,Jose A. Caminero,Mina Gaga,Gina Gualano,Alena Skrahina,Ivan Solovic,Giorgia Sulis,Marina Tadolini,Valentina Alarcon Guizado,Saverio De Lorenzo,Aurora Jazmín Roby Arias,Anna Scardigli,Onno W. Akkerman,Alena Aleksa,Janina Artsukevich,Vera Auchynka,Eduardo Henrique Bonini,Felix Antonio Chong Marin,Lorena Collahuazo López,Gerard de Vries,Simone Dore,Heinke Kunst,Alberto Matteelli,Charalampos Moschos,Fabrizio Palmieri,Apostolos Papavasileiou,Marie-Christine Payen,Andrea Piana,Antonio Spanevello,Dante Vargas Vasquez,Pietro Viggiani,Veronica White,Alimuddin Zumla,Giovanni Battista Migliori +39 more
TL;DR: It is suggested that meropenem/clavulanate is more effective than imipenem/ clavULanate in treating MDR/XDR-TB patients and safe and more effective in treating non-drug-resistant tuberculosis patients.
Journal ArticleDOI
Ertapenem in the treatment of multidrug-resistant tuberculosis: first clinical experience.
Simon Tiberi,Lia D'Ambrosio,Saverio De Lorenzo,Pietro Viggiani,Rosella Centis,Giovanni Sotgiu,Jan Wilem C. Alffenaar,Giovanni Battista Migliori +7 more
TL;DR: Etrtapenem may be useful for MDR/XDR-TB to simplify administration of carbapenem when the patient is at home and the necessary drugs expensive.